Funding body, European Commission provides some breathing room for Horizon2020 projects due to impacts of COVID-19.
EDEN2020 has been granted a 6-month no-cost extension from its funding body, the European Commission. COVID-19 has had a considerable impact on the progress of EDEN2020’s preclinical work. Like many Horizon2020 projects involved in clinical trials, EDEN2020 was required to halt all experimental work as a result of the pandemic and the European Commission (EC) have recognised this. The EDEN2020 consortium hope it will be safe to return to the operating theatre and complete system testing in the coming months, then using the extension to complete the last remaining work on the in vivo trials. The Consortium are very appreciative for this no-cost extension and are positive that this will maximise the expected impacts of the EDEN2020 project.
This extension means EDEN2020 will have an expected project closure date of 31st March 2021.
For further information, the European Commission has placed up-to-date information on its website regarding COVID-19 response and action.